Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of saikogenin A in treating neurodegeneration disorders

A degenerative disease and neurodegenerative technology, applied in the field of medicine, can solve the problems of complex pathogenesis of ND, special parts, lack of therapeutic drugs, etc.

Inactive Publication Date: 2019-06-14
NINGXIA MEDICAL UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complex pathogenesis and special location of ND, there is still a lack of effective therapeutic drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of saikogenin A in treating neurodegeneration disorders
  • Application of saikogenin A in treating neurodegeneration disorders
  • Application of saikogenin A in treating neurodegeneration disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: The Griess colorimetric method was used to investigate the effect of saikosaponin A on LPS-induced NO release from microglial cells;

[0026] Cell line: mouse microglial cell line BV-2;

[0027] Drugs: LPS; saikosaponin A; minocycline (MINO).

[0028] method:

[0029] (1) Culture of mouse microglial cell line BV-2:

[0030] The cell culture solution was prepared based on DMEM medium, containing 10% FBS, 100 U penicillin and 100 U streptomycin, and 50 μM 2-mercaptoethanol (all final concentrations). Place BV-2 microglial cells in a cell culture incubator at a cell density of about 4×105 cells / ml at 5% CO2 and 37°C, and observe the growth of the cells regularly until the area of ​​the cells adheres to the culture flask is about When the bottom area was 50-60%, the cells were digested with trypsin and passaged, and then continued to culture. Take 3-7 generations of cells for experiments.

[0031] (2) Determination of nitrite content:

[0032] Experimental ...

Embodiment 2

[0038] Example 2: The DCFH oxidation method was used to investigate the effect of saikogenin A on the release of ROS from microglial cells induced by LPS;

[0039] Cell line: mouse microglial cell line BV-2;

[0040] Drugs: LPS; saikosaponin A; MINO.

[0041]Detection method: Take BV-2 cells in the logarithmic growth phase, inoculate the cells in a 6-well plate with fresh serum-free DMEM medium, and the cell density is 3×10 5 cells / ml, inoculum volume 600μl / well, placed in an incubator at 37°C, 5% CO 2 cultivated under conditions. After the cells adhered to the wall for 3 hours, the culture solution was carefully sucked out, and according to the experimental group, the cells were replaced with different drugs prepared in serum-free DMEM culture solution to incubate the cells. At the same time, a blank control group was set up, and each group was set with 3 replicate wells, and the drug addition to the cells continued. After culturing for 2-4 hours, collect the supernatant, ...

Embodiment 3

[0045] Example 3: The ELISA method was used to investigate the effect of saikosapogenin A on the release of LPS-induced microglial tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β);

[0046] Cell line: mouse microglial cell line BV-2;

[0047] Drugs: LPS; saponin A; MINO.

[0048] Detection method: Take BV-2 cells in the logarithmic growth phase, inoculate the cells in a 6-well plate with fresh serum-free DMEM medium, and the cell density is 3×10 5 cells / ml, inoculum volume 600μl / well, placed in an incubator at 37°C, 5% CO 2 cultivated under conditions. After the cells adhered to the wall for 3 hours, the culture solution was carefully sucked out, and according to the experimental group, the cells were replaced with different drugs prepared in serum-free DMEM culture solution to incubate the cells. At the same time, a blank control group was set up, and each group was set with 3 replicate wells, and the drug addition to the cells continued. After culturing for 2-4 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses new application of saikogenin A in treating neurodegeneration disorders. As is proved by pharmacological experiments, the saikogenin A can significantly inhibit release of microglial cell inflammation factors NO, ROS, TNF-alpha and IL-1beta induced by LPS. As is shown by the result, the saikogenin A has an obvious inhibiting effect on the microglial cell neuroinflammation induced by the LPS. Therefore, the compound can be used for preparing a drug for preventing and / or treating neuroinflammations and relevant central nervous degenerative diseases, and has high clinicalapplication value and a good development prospect.

Description

Technical field: [0001] The invention relates to the technical field of medicine, in particular to the use of saikosaponin A in treating neurodegenerative diseases. Background technique: [0002] Neurodegenerative diseases (neurodegeneration disorders, ND) are a group of chronic progressive neurological diseases based on primary neuron degeneration, mainly including Alzheimer's disease (Alzheimer's disease, AD), Parkinson's disease (Parkinson's disease) , PD), multiple sclerosis (multiple sclerosis, MS), Huntington's disease (Huntington's disease, HD) and so on. [0003] As the world's population ages, the incidence of neurodegenerative diseases is on the rise. For example, the prevalence rate of AD among people over 60 years old in my country is 5.1%, and that among people over 85 years old is 30%. The prevalence of PD is second only to AD, and mainly occurs in people over middle age, with a prevalence rate of 2% among people over 65 years old. After the onset of the dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61P25/28A61P25/00A61P29/00
Inventor 李娟姚遥陈菲李玮琦
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com